The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients
Hepatology. 2021 May 18. doi: 10.1002/hep.31909. Online ahead of print.
Magdalena Meszaros1, Régine Truchi2, Denis Ouzan3, Albert Tran2, Marc Bourliere4, Georges Philippe Pageaux1
Author information
1Hépato-Gastroentérologie, Hôpital Saint-Eloi, Montpellier, France.
2Université Côte d'Azur, CHU de Nice, Digestive Center, Nice, France.
3Unité d'Hépatologie, Institut Arnault Tzanck, Saint Laurent du Var, France.
4Hôpital Saint Joseph, Service d'Hépatologie, Marseille, France.
Abstract
Pangenotypic direct-acting antiviral (DAA) drugs have a hepatitis C (HCV) cure rate of >95% in almost all treated patients. When DAA treatment fails, retreatment must be guided by virus resistance profiles, and phase III trials have reported sustained virological responses (SVR) of 96-98% after a 12-week course of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX).